Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011092199 - MUTATED XMRV ENV PROTEINS IN THE IMMUNOSUPPRESSIVE DOMAIN

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. A mutated XMRV ENV protein in which the immunosuppressive domain of the wild type XMRV ENV protein presents at least one mutation, said immunosuppressive domain of the wild type XMRV ENV protein consisting of the amino acid sequence SEQ ID NO : 1, (LQNRRGLDILFLKEGGLC AA) ,

said at least one mutation being such that E which is at the position 14 of SEQ ID NO : 1 is substituted by R, H or K.

2. A mutated XMRV ENV protein according to claim 1, in which the immunosuppressive domain of the wild type XMRV ENV protein presents two mutations, said immunosuppressive domain of the wild type XMRV ENV protein consisting of the amino acid sequence SEQ ID NO : 1, (LQNRRGLDILFLKEGGLC AA) ,

said two mutations being such that :

E which is at the position 14 of SEQ ID NO : 1 is substituted by R, H or K and

A which is at the position 20 of SEQ ID NO: 1, is such that it ensures that the structure of the viral XMRV ENV protein is conserved.

3. The mutated XMRV ENV according to claim 1, wherein said two mutations are such that

E which is at the position 14 of SEQ ID NO : 1 is substituted by R, H or K, and

A which is at the position 20 of SEQ ID NO: 1 is substituted by F, M, Y or W.

4. The mutated XMRV ENV according to claim 1 , wherein said two mutations are such that

E which is at the position 14 of SEQ ID NO : 1 is substituted by R, and

A which is at the position 20 of SEQ ID NO: 1 is substituted by F.

5. The mutated XMRV ENV according to anyone of claims 1 to 4, wherein wild type XMRV ENV protein consists of the amino acid sequence chosen among the group comprising: SEQ ID NO : 2, (YP 12363.1), SEQ ID NO : 3, (ABB83229.1), SEQ ID

NO : 4, (ACY30457.1), SEQ ID NO : 5, (ABM47429.1), SEQ ID NO : 6, (ACY3046.1), SEQ ID NO : 7, (ABB83226.1), and SEQ ID NO : 8, (ACY30462.1).

6. The mutated XMRV ENV according to anyone of claims 1 to 5, wherein said mutated XMRV ENV protein consists of the amino acid sequence chosen among the group comprising: SEQ ID NO : 9, SEQ ID NO : 10, SEQ ID NO : 11, SEQ ID NO : 12, SEQ ID NO : 13, SEQ ID NO : 14, SEQ ID NO : 15, SEQ ID NO : 16, SEQ ID NO : 17, SEQ ID NO : 18, SEQ ID NO : 19, SEQ ID NO : 20, SEQ ID NO : 21, SEQ ID NO : 22 and SEQ ID NO : 23.

7. A nucleic acid coding for the mutated XMRV ENV protein as defined in anyone of claims 1 to 6.

8. A vector comprising a nucleic acid molecule according to claim 7, preferably said vector further comprising nucleic acid sequences allowing the expression of said nucleic acid molecule.

9. The vector according to claim 8, further comprising nucleic acid sequences allowing the expression of another XMRV protein, in particular a nucleic acid molecule coding for GAG and/or PRO and/or POL XMRV proteins.

10. The vector according to claim 8 or 9, said vector being a viral vector, in particular a pox vector chosen among a fowlpox, a canarypox, or a MVA (modified vaccinia virus Ankara) vector, an adenoviral vector, a measles vector, or a CMV (cytomegalovirus) vector.

11. A composition, comprising:

• a mutated XMRV ENV protein, as defined in anyone of claims 1 to 6, or

• a nucleic acid, as defined in anyone of claims 7, or

• a vector as defined in anyone of claims 8 to 10,

in association with a pharmaceutically acceptable carrier.

12. The composition, according to claim 11, for its use a medicine.

13. The composition, according to claim 11 or 12,

• a mutated XMRV ENV protein, as defined in anyone of claims 1 to 6, or

• a nucleic acid, as defined in anyone of claims 7, or

· a vector as defined in anyone of claims 8 to 10,

for its use for the prevention and/or the treatment of pathologies involving the XMRV virus.

14. The composition, according to claim 13, wherein pathologies involving the XMRV virus are chosen among prostate cancer and chronic fatigue syndrome.

• a mutated XMRV ENV protein, as defined in anyone of claims 1 to 6, or

• a nucleic acid, as defined in anyone of claims 7, or

• a vector as defined in anyone of claims 8 to 10,

for its use for the prevention and/or the treatment of pathologies involving the XMRV virus.